Therapy News and Research

RSS

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

Cyberonics, Inc. today announced that the AspireHC™ (High Capacity) generator for use in vagus nerve stimulation (VNS) therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.

2 Feb 2011

New compound appears to prevent pain crises in sickle cell disease: GHSU

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.

1 Feb 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

BioMarin Pharmaceutical announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome.

1 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

Kinetic Concepts fourth quarter net earnings increase 12% to $74.0 million

Kinetic Concepts, Inc. today reported fourth quarter and full year 2010 total revenue of $527.5 million and $2.02 billion, respectively, compared to $526.8 million and $1.99 billion in the corresponding periods of the prior year.

1 Feb 2011

Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien plc today reported results for the first quarter of fiscal 2011 (October-December 2010). First-quarter net sales of $2.77 billion increased 5% from the $2.64 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

1 Feb 2011

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.

1 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

1 Feb 2011

CAM therapies are more pronounced among whites than racial and ethnic minorities

The use of complementary and alternative medicine therapies experienced a significant growth in the United States in the last decade, and a new analysis finds that CAM use becomes more likely when access to conventional care has been restricted.

1 Feb 2011

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

Untreated or poorly managed diabetes can cause severe health complications such as kidney failure, blindness, heart disease, stroke and nerve damage. To help diabetic patients more easily care for their condition, Loyola has opened the Comprehensive Diabetes Care Clinic at Loyola Center for Health at Hickory Hills.

1 Feb 2011

Scientists devise safer way to create iPS cells

Researchers at Johns Hopkins have found a better way to create induced pluripotent stem (iPS) cells-adult cells reprogrammed with the properties of embryonic stem cells-from a small blood sample. This new method, described last week in Cell Research, avoids creating DNA changes that could lead to tumor formation.

1 Feb 2011

MSPP announces formation of spirituality and psychotherapy center

Most people have some form of spiritual practice or belief system that helps them find meaning in life. This orientation can profoundly impact the psychotherapeutic process, according to the founders of a formal center for the study of spirituality and psychotherapy at the Massachusetts School of Professional Psychology in West Roxbury.

1 Feb 2011

Favorable clinical results from Endologix's Nellix technology against EVAR

Endologix, developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm.

1 Feb 2011

DNA Direct implements four new health plan clients for molecular diagnostic and genetic tests

DNA Direct, a wholly owned subsidiary of Medco Health Solutions, Inc. and a provider of guidance and decision support for genomic medicine, today announced four new health plan clients that are implementing DNA Direct's Policy & Benefit Support Program for molecular diagnostic and genetic tests.

1 Feb 2011

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

High levels of circulating DNA may indicate faster progression of lung cancer and lower overall survival, according to a study published in the February edition of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Therapy News and Research

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

New compound appears to prevent pain crises in sickle cell disease: GHSU

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Kinetic Concepts fourth quarter net earnings increase 12% to $74.0 million

Covidien first-quarter net sales increase 5% to $2.77 billion

Elsevier announces publication of two position statements from EMAS in Maturitas journal

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

CAM therapies are more pronounced among whites than racial and ethnic minorities

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

Scientists devise safer way to create iPS cells

MSPP announces formation of spirituality and psychotherapy center

Favorable clinical results from Endologix's Nellix technology against EVAR

DNA Direct implements four new health plan clients for molecular diagnostic and genetic tests

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News